[Cefuroxime axetil, a new oral cephalosporin for treating infections of the ORL field: clinical synthesis].
J F Westphal
Index: Rev. Laryngol. Otol. Rhinol. (Bord.) 111(5) , 503-5, (1990)
Full Text: HTML
Abstract
Cefuroxime axetil (C.A.E.) is a broad spectrum cephalosporin, suitable for oral route. Its antibacterial activity includes all the pathogens usually responsible for E.N.T. infection, with low M.I.C.'s: H. influenzae, S. pneumoniae, S. aureus, S. pyogene. The stability of the drug against betalactamases, especially those produced by H. influenzae, associated with good bio availability (50%) and tissue penetration (30%) account for the potent in vivo bactericidal activity and clinical efficacy of cefuroxime axetil. More than 1,000 patients had been enrolled in controlled clinical trials: the success rates yielded by C.A.E. were 98%, 96% and 91%, respectively for pharingitis/tonsilitis, otitis media and acute sinusitis. C.A.E. is at least as effective as amoxycillin/clavulanic acid and safety appears to be better.
Related Compounds
Related Articles:
Cefuroxime axetil: an updated review of its use in the management of bacterial infections.
2001-01-01
[Drugs 61(10) , 1455-500, (2001)]
Design and characterization of cefuroxime axetil biphasic floating minitablets.
2015-01-01
[Drug Deliv. 22(1) , 125-35, (2014)]
Cefuroxime axetil in the treatment of sinusitis. A review.
1994-02-01
[Arch. Fam. Med. 3(2) , 165-75, (1994)]
1988-09-01
[Jpn. J. Antibiot. 41(9) , 1181-93, (1988)]
[Oral cephalosporins. Role of cefuroxime-axetil].
1988-01-01
[Therapie. 43 Suppl 4 , 343-9, (1988)]